𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis

✍ Scribed by B. Tayyebeh Sadatipour; Judith M. Greer; Dr. Michael P. Pender

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
434 KB
Volume
44
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

Plasma samples from 70 patients with multiple sclerosis (MS), 41 patients with other neurological diseases (OND), and 38 healthy subjects were examined for antibodies against gangliosides GM1, GM3, GD1a, GD1b, and GD3 using enzyme-linked immunosorbent assays. The percentages of subjects with increased anti-GM3 responses were significantly higher in the primary progressive MS (56.3%) and secondary progressive MS (42.9%) groups than in the relapsing-remitting MS (2.9%), healthy subject (2.6%), and OND (14.6%) groups. Elevated antiganglioside antibodies may be secondary to axonal damage or may be a cause of axonal damage and accumulating disability in progressive MS. In either case, they may serve as a marker of axonal damage in MS.

πŸ“œ SIMILAR VOLUMES

Increases levels of circulating intercel
Increases levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy
✍ Dr.; MD; PhD N. Tsukada; MD; PhD K. Miyagi; MD; PhD M. Matsuda; MD; PhD N. Yanag πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 445 KB πŸ‘ 2 views

We evaluated the presence of soluble intercellular adhesion molecule-1 (SICAM-I) antigen in the sera of patients with multiple sclerosis and human T-lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM) using an enzyme-linked immunosorbent assay. Patients with multiple sclerosis in the acti

Glatiramer acetate in primary progressiv
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
✍ Jerry S. Wolinsky; Ponnada A. Narayana; Paul O'Connor; Patricia K. Coyle; Corey πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 349 KB πŸ‘ 2 views

## Abstract ## Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. ## Methods A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind tri